Área de Farmacología, Departamento de Ciencias Biomédicas, Universidad de Alcalá, E-28871 Alcalá de Henares, Unidad Asociada al Instituto de Química Médica del CSIC, Madrid, Spain.
Org Biomol Chem. 2013 May 14;11(18):3046-56. doi: 10.1039/c3ob40407b.
Ten novel taxanes bearing modifications at the C2 and C13 positions of the baccatin core have been synthesized and their binding affinities for mammalian tubulin have been experimentally measured. The design strategy was guided by (i) calculation of interaction energy maps with carbon, nitrogen and oxygen probes within the taxane-binding site of β-tubulin, and (ii) the prospective use of a structure-based QSAR (COMBINE) model derived from an earlier series comprising 47 congeneric taxanes. The tubulin-binding affinity displayed by one of the new compounds (CTX63) proved to be higher than that of docetaxel, and an updated COMBINE model provided a good correlation between the experimental binding free energies and a set of weighted residue-based ligand-receptor interaction energies for 54 out of the 57 compounds studied. The remaining three outliers from the original training series have in common a large unfavourable entropic contribution to the binding free energy that we attribute to taxane preorganization in aqueous solution in a conformation different from that compatible with tubulin binding. Support for this proposal was obtained from solution NMR experiments and molecular dynamics simulations in explicit water. Our results shed additional light on the determinants of tubulin-binding affinity for this important class of antitumour agents and pave the way for further rational structural modifications.
已经合成了十种在巴卡丁核心的 C2 和 C13 位置进行修饰的新型紫杉烷,并对其与哺乳动物微管蛋白的结合亲和力进行了实验测量。设计策略的指导原则是:(i)在β-微管蛋白的紫杉烷结合部位用碳、氮和氧探针计算相互作用能量图,(ii)预期使用源自早期包含 47 种同类紫杉烷的基于结构的 QSAR(COMBINE)模型。其中一种新型化合物(CTX63)的微管蛋白结合亲和力被证明高于多西他赛,并且更新的 COMBINE 模型为 57 种研究化合物中的 54 种提供了实验结合自由能与一组加权残基配体-受体相互作用能之间的良好相关性。原始训练系列中的其余三个异常值的共同点是对结合自由能有很大的不利熵贡献,我们将其归因于紫杉烷在水溶液中的预组织,其构象与与微管蛋白结合不兼容。来自溶液 NMR 实验和明确水中的分子动力学模拟的结果为这一重要类抗肿瘤药物的微管蛋白结合亲和力的决定因素提供了额外的证据,并为进一步的合理结构修饰铺平了道路。